Review of the use of hepatitis B core antibody-positive kidney donors.

Published

Journal Article (Review)

This article reviews the risks of transplanting hepatitis B core antibody (anti-HBc)-positive (+) kidneys and strategies to minimize the risks to the recipient. In the United States, there is a shortage of kidneys available for transplantation. Presently, 4% of kidneys transplanted are anti-HBc (+). In published retrospective studies, the serologic conversion rate for recipients of anti-HBc (+) kidneys varied between 0% and 27%; and the development of elevated hepatic transaminases varied between 0% and 26%. Only one published article had a trend toward increased risk of graft loss. Other published studies had no significant difference in graft or patient survival. Factors that influence the risk of transmission include hepatitis B viral load, vaccination, and antiviral therapy. If the donor is anti-HBc (+) and hepatitis B DNA negative, the risk of transmission is negligible; unfortunately, this information may not be available at the time of transplant. Vaccinated recipients with a protective hepatitis B surface antibody of at least 10 mIU/mL had a 4% conversion rate compared with 10% in recipients with antibody levels not exceeding 10 mIU/mL. Both hepatitis B immunoglobulin and lamivudine have been used in recipients of anti-HBc (+) kidneys to decrease seroconversion with success. The data do support the use of anti-HBc (+) kidneys if precautions are taken. The recipients should be informed of the risk, should be vaccinated with an adequate response, and should have surveillance serologies performed.

Full Text

Duke Authors

Cited Authors

  • Ouseph, R; Eng, M; Ravindra, K; Brock, GN; Buell, JF; Marvin, MR

Published Date

  • October 2010

Published In

Volume / Issue

  • 24 / 4

Start / End Page

  • 167 - 171

PubMed ID

  • 20655722

Pubmed Central ID

  • 20655722

Electronic International Standard Serial Number (EISSN)

  • 1557-9816

Digital Object Identifier (DOI)

  • 10.1016/j.trre.2010.05.001

Language

  • eng

Conference Location

  • United States